Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
BPC-157 Arginate (Stable Form)
BPC-157 Arginine Salt, BPC-157-Arg
The arginine salt form of BPC-157, developed to improve stability and shelf life compared to the standard acetate salt. BPC-157 arginate maintains the same gastric pentadecapeptide sequence but uses arginine as the counter-ion, which provides better stability at room temperature and in solution. This form is increasingly preferred by compounding pharmacies and researchers.
The oral formulation of BPC-157, distinct from the injectable form in its bioavailability profile and primary applications. While injectable BPC-157 is used for systemic and musculoskeletal healing, oral BPC-157 is particularly relevant for gastrointestinal conditions where direct gut exposure may be more important than systemic absorption.
Same mechanism as standard BPC-157 — upregulates growth factor expression (VEGF, FGF, EGF), promotes angiogenesis, modulates nitric oxide pathways, and interacts with the dopaminergic system. The arginine counter-ion does not change the peptide's pharmacological activity but improves chemical stability, particularly in aqueous solution.
Same mechanism as injectable BPC-157 — promotes angiogenesis, upregulates growth factors, and modulates nitric oxide synthesis. In oral form, the peptide is exposed directly to the GI tract mucosa before any systemic absorption, potentially making it more effective for gut-specific conditions.
- Gut healing and GI repair
- Tendon and ligament recovery
- Muscle injury repair
- Neuroprotection
- Stable alternative to BPC-157 acetate
- Inflammatory bowel disease (IBD)
- Leaky gut and intestinal permeability
- NSAID-induced gastric damage
- Gut healing and GI protection
- Esophageal and stomach ulcers
- Same risk profile as standard BPC-157
- No FDA-approved human trials
- Theoretical concerns about growth factor upregulation
- Quality varies between sources
- Lower and more variable systemic bioavailability than injectable
- Limited human clinical data for oral form specifically
- Quality of oral preparations varies significantly
- Long-term safety unknown
Same regulatory status as BPC-157. Removed from Category 2 on April 15, 2026. Scheduled for PCAC review on July 23, 2026 (Day 1). The arginate form is not separately categorized by the FDA — it falls under the same BPC-157 regulatory umbrella.
PCAC: July 23, 2026
Shares the same regulatory status as injectable BPC-157 — removed from FDA 503A Category 2 effective April 22, 2026. Scheduled for PCAC review on July 23, 2026. The oral form is particularly relevant for the FDA's listed indication of ulcerative colitis. Compounding not yet authorized.
PCAC: July 23, 2026
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.